Latuda (Schizophrenia) - Analysis and Forecasts to 2020

Latuda (Schizophrenia) - Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “Latuda (Schizophrenia) - Analysis and Forecasts to 2020” provides Latuda sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Schizophrenia market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Latuda including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Latuda including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2011-2020 for Latuda in each of the seven major markets

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Latuda – Analysis and Forecasts from 2011 to 2020
2 Table of Contents 2
2.1 List of Tables 3
2.2 List of Figures 3
3 Introduction 4
3.1 Schizophrenia 4
3.2 Symptoms 4
3.3 Schizophrenia Market 4
3.4 Epidemiology 4
3.5 Etiology 5
3.5.1 Genetic Factors 5
3.5.2 Environmental Factors 5
3.5.3 Abnormal Brain Structure 6
3.6 GlobalData Report Guidance 6
4 Schizophrenia: Market Characterization 7
4.1 Schizophrenia Market 7
4.2 Schizophrenia Market Forecasts and CAGR 7
4.3 Drivers of Schizophrenia Therapeutics Market 7
4.3.1 Patent Expiry of Leading Marketed Drugs 8
4.3.2 Increasing Patient Pool 8
4.3.3 High Prescription Rates 8
4.3.4 Low Patient Compliance Rate 8
4.3.5 High Unmet Need 8
5 Classification of Schizophrenia 9
5.1 Age of Onset of Schizophrenia 9
5.1.1 Pediatric / Adolescent / Childhood Schizophrenia 9
5.1.2 Adult Schizophrenia 10
5.2 Associated Symptoms 10
5.2.1 Paranoid Schizophrenia 10
5.2.2 Disorganized Schizophrenia 10
5.2.3 Catatonic Schizophrenia 10
5.2.4 Residual Schizophrenia 10
5.2.5 Undifferentiated Disorder 10
6 Treatment for Schizophrenia 11
6.1 Crisis Resolution Teams (CRT) 11
6.2 Voluntary and Compulsory Detention 11
6.3 Antipsychotics 11
6.3.3 WARNING: Increased Mortality in Elderly Patients with Dementia-Related Psychosis 12
7 Latuda 13
7.1 Introduction 13
7.2 Mechanism of Action 13
7.3 Clinical Studies 13
7.4 Development Status of Latuda 14
7.5 Factors Affecting the Sales of Latuda 14
7.5.1 Better Safety Profile 14
7.5.2 High Competition 15
7.5.3 Market Exclusivity 15
7.5.4 Failure of Pan–Asia Phase III Trial 15
7.6 Drug Evaluation 15
7.6.1 Drug Risk Benefit Score 15
7.6.2 Intensity of Competition 16
7.7 Sales Forecasts 17
7.7.1 Target Patient Pool of Latuda 17
7.7.2 Dosing 18
7.7.3 Market Penetration 18
7.7.4 Annual Cost of Therapy 18
7.7.5 Sales Estimates of Latuda 20
8 Schizophrenia Market: Appendix 29
8.1 Market Definitions 29
8.2 Abbreviations 29
8.3 Research Methodology 29
8.4 Contact Us 31
8.5 Disclaimer 31
8.6 Sources 32